Photo from wikipedia
Key Points Question Is there equitable geographic access to chimeric antigen receptor–T cells (CAR-T) and bispecific antibodies trials for multiple myeloma in the US? Findings In this cross-sectional study of… Click to show full abstract
Key Points Question Is there equitable geographic access to chimeric antigen receptor–T cells (CAR-T) and bispecific antibodies trials for multiple myeloma in the US? Findings In this cross-sectional study of data from 69 clinical trials in the US, 34% of the states analyzed had no CAR-T or bispecific clinical trial openings. There are limited open sites in states with the highest percentages of Black residents. Meaning These results suggest that the current distribution of CAR-T and bispecific antibodies trials for multiple myeloma does not allow for equitable access for Black patients.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!